ALNY Q4 2019 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72M+240.8% YoY

Gross Profit

$60M83.0% margin

Operating Income

-$298M-415.8% margin

Net Income

-$276M-385.3% margin

EPS (Diluted)

$-2.47

QoQ Revenue Growth

+2.3%

Cash Flow

Operating Cash Flow

-$196M

Free Cash Flow

-$235M

Stock-Based Comp.

$66M

Balance Sheet

Total Assets

$2.4B

Total Liabilities

$956M

Stockholders' Equity

$1.4B

Cash & Equivalents

$547M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72M	$21M	+240.8%
Gross Profit	$60M	$19M	+207.2%
Operating Income	-$298M	-$220M	-35.3%
Net Income	-$276M	-$211M	-30.6%

Revenue Segments

Product

$56M100%

Geographic Segments

UNITED STATES

$55M66%

Non-US Or Europe

$28M34%